The Source for Whistleblowers, Journalists, Legislators & Academics

J&J Unit Pays $85M Fine for Misbranding Heart Drug—9/14/11

Johnson & Johnson’s Scios unit will pay $85 million in penalties for misbranding the heart drug Natrecor. Under the False Claims Act, the U.S. alleged that Johnson & Johnson illegally marketed Natrecor for off-label “serial outpatient infusions” not yet approved by the FDA. According to the U.S., this practice has led to “substantial amounts” of false claims being submitted to the Medicare program.
Read more at:

Related posts

Democracy Misconceived

By William Nettles and Reuben Guttman There is a misconception among many that democracy...

The Art of Advocacy

Judges are now insisting that plaintiffs make their case with facts instead of merely...

Rapamune In the News

The Justice Department on Tuesday joined a whistleblower lawsuit against Pfizer and its subsidiary...

Comments are currently closed.